SCHEMBL6412685

SCHEMBL6412685

CCNCc1cc([N+](=O)[O-])ccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25C P30307 1/20 0.53
APP P05067 1/20 0.51
MEN1 O00255 1/20 0.49
CRHBP P24387 1/20 0.49
KMT2A Q03164 1/20 0.49
CRHR2 Q13324 1/20 0.49
ERN1 O75460 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GPR35 Q9HC97 1/20 0.49
ALB P02768 1/20 0.48
CTSB P07858 2/20 0.48
GAA P10253 1/20 0.47
THRB P10828 1/20 0.47
ITGA4 P13612 4/20 0.47
ITGB7 P26010 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11509750 0.90 APP (0.56) CDC25CAPPMEN1CRHBPKMT2A
SCHEMBL6687191 0.84 CDC25C (0.54) CDC25CAPPMEN1CRHBPKMT2A
SCHEMBL5170527 0.84 CTSB (0.54) CDC25CAPPMEN1CRHBPKMT2A
SCHEMBL4231830 0.83 ALDH1A1 (0.58) APPMEN1CRHBPKMT2ACRHR2
SCHEMBL9827648 0.82 CDC25C (0.55) CDC25CAPPMEN1CRHBPKMT2A
SCHEMBL27463698 0.82 SMN1; SMN2 (0.53) CDC25CAPPERN1ALDH1A1TP53
SCHEMBL25188714 0.80 ITGA4 (0.56) CDC25CAPPMEN1CRHBPKMT2A
SCHEMBL6607465 0.80 KMT2A (0.57) APPMEN1CRHBPKMT2ACRHR2
SCHEMBL17434485 0.80 MAPT (0.50) MEN1CRHBPKMT2ACRHR2ALDH1A1
Formaldehyde SCHEMBL27590299 0.79 SMN1; SMN2 (0.50) CDC25CAPPERN1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050282872-A1 Novel thyroid receptor ligands and method II HANGELAND JON 2005-12-22 US claimed
US-20250325547-A1 ANTI-SARS-COV-2 DRUG KAGOSHIMA UNIVERSITY (JP) 2025-10-23 US disclosed
EP-4431151-A1 ANTI-SARS-COV-2 DRUG Kagoshima University (JP) 2024-09-18 EP disclosed
CN-118302413-A Anti-SARS-CoV-2 medicine 国立大学法人鹿儿岛大学 2024-07-05 CN disclosed
WO-2023085392-A1 ANTI-SARS-COV-2 DRUG 国立大学法人鹿児島大学 2023-05-19 WO disclosed
EP-0576088-B1 Photographic material and process comprising a coupler capable of forming a wash-out dye EASTMAN KODAK CO (US) 1999-08-11 EP disclosed
US-5288593-A Photographic material and process comprising a coupler capable of forming a wash-out dye (Q/Q) EASTMAN KODAK COMPANY (US) 1994-02-22 US disclosed
US-5279929-A Coupler forms a compound that washes out during development EASTMAN KODAK COMPANY (US) 1994-01-18 US disclosed
EP-0577182-A1 Photographic material and process comprising a coupler capable of forming a wash-out dye (Q/Q) EASTMAN KODAK COMPANY (US) 1994-01-05 EP disclosed
EP-0576052-A1 Method of forming a photographic coupler capable of forming a wash-out dye EASTMAN KODAK COMPANY (US) 1993-12-29 EP disclosed
EP-0576089-A2 Photographic material and process comprising a coupler capable of forming a wash-out dye EASTMAN KODAK COMPANY (US) 1993-12-29 EP disclosed
EP-0576087-A1 Photographic material and process comprising a coupler capable of forming a wash-out dye (Q/C) EASTMAN KODAK COMPANY (US) 1993-12-29 EP disclosed
EP-0576088-A1 Photographic material and process comprising a coupler capable of forming a wash-out dye (C/C) EASTMAN KODAK COMPANY (US) 1993-12-29 EP disclosed
US-5264583-A Photographic coupler and method of making the same EASTMAN KODAK COMPANY (US) 1993-11-23 US disclosed
US-5264582-A Reaction of hydroxyaryl aldehyde or ketone with a halomethyl compound to form ether compound and reducing the product then halogenation and reaction with photographic coupler EASTMAN KODAK COMPANY (US) 1993-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282872-A1 Novel thyroid receptor ligands and method II TSHR, THRB, THRA CDC25C 2692/4885APP 3804/4885MEN1 3521/4885
US-20250325547-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, AGTR2 CDC25C 2017/4885APP 4133/4885MEN1 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.